Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 5/20 | 1.00 |
| ▸ | DPP4 | P27487 | 5/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.61 |
| ▸ | NPC1 | O15118 | 5/20 | 0.61 |
| ▸ | RAB9A | P51151 | 5/20 | 0.61 |
| ▸ | TSHR | P16473 | 3/20 | 0.61 |
| ▸ | CASP1 | P29466 | 2/20 | 0.61 |
| ▸ | CASP7 | P55210 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19397816 | 0.83 | DPP4 (0.71) | ANPEPDPP4ALDH1A1NPC1RAB9A | |
| SCHEMBL12665488 | 0.83 | DPP4 (0.71) | ANPEPDPP4ALDH1A1NPC1RAB9A | |
| SCHEMBL10658930 | 0.82 | ANPEP (0.69) | ANPEPDPP4ALDH1A1NPC1RAB9A | |
| SCHEMBL17326771 | 0.80 | DPP4 (0.67) | ANPEPDPP4ALDH1A1MEN1KMT2A | |
| SCHEMBL10491139 | 0.80 | DPP4 (0.68) | ANPEPDPP4ALDH1A1TSHRMEN1 | |
| SCHEMBL2818285 | 0.80 | ANPEP (1.00) | ANPEPDPP4ALDH1A1NPC1RAB9A | |
| SCHEMBL12021927 | 0.78 | DPP4 (0.64) | ANPEPDPP4ALDH1A1NPC1RAB9A | |
| SCHEMBL6923519 | 0.77 | DPP4 (0.63) | ANPEPDPP4ALDH1A1MEN1KMT2A | |
| SCHEMBL9468849 | 0.77 | NPC1 (0.67) | ANPEPDPP4ALDH1A1NPC1RAB9A | |
| SCHEMBL1250706 | 0.76 | ANPEP (0.66) | ANPEPDPP4ALDH1A1HSD17B10MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2769715-A2 | Methods for treating autoimmune disorders, and reagents related thereto | TRUSTEES OF TUFTS COLLEGE (US) | 2014-08-27 | — | — | EP | disclosed |
| US-8796294-B2 | Inhibitors of the hedgehog pathway | EXELIXIS PATENT COMPANY LLC (US) | 2014-08-05 | — | — | US | disclosed |
| US-8796294-B2 | Inhibitors of the hedgehog pathway | EXELIXIS PATENT COMPANY LLC (US) | 2014-08-05 | — | — | US | disclosed |
| US-8796294-B2 | Inhibitors of the hedgehog pathway | EXELIXIS PATENT COMPANY LLC (US) | 2014-08-05 | — | — | US | disclosed |
| US-8754092-B2 | Inhibitors of the hedgehog pathway | EXELIXIS PATENT COMPANY LLC (US) | 2014-06-17 | — | — | US | disclosed |
| US-8754092-B2 | Inhibitors of the hedgehog pathway | EXELIXIS PATENT COMPANY LLC (US) | 2014-06-17 | — | — | US | disclosed |
| US-8754092-B2 | Inhibitors of the hedgehog pathway | EXELIXIS PATENT COMPANY LLC (US) | 2014-06-17 | — | — | US | disclosed |
| US-8410053-B2 | Methods for treating autoimmune disorders, and reagents related thereto | TRUSTEES OF TUFTS COLLEGE (US) | 2013-04-02 | — | — | US | disclosed |
| EP-2527330-A1 | Inhibitors of the hedgehog pathway | Exelixis, Inc. (US) | 2012-11-28 | — | — | EP | disclosed |
| EP-2527330-A1 | Inhibitors of the hedgehog pathway | Exelixis, Inc. (US) | 2012-11-28 | — | — | EP | disclosed |
| US-8222263-B2 | Inhibitors of hedgehog pathway | EXELIXIS PATENT COMPANY LLC (US) | 2012-07-17 | — | — | US | disclosed |
| EP-2134695-A1 | INHIBITORS OF THE HEDGEHOG PATHWAY | Exelixis, Inc. (US) | 2009-12-23 | — | — | EP | disclosed |
| US-20090105211-A1 | INHIBITORS OF HEDGEHOG PATHWAY | EXELIXIS, INC. (US) | 2009-04-23 | — | — | US | disclosed |
| US-20090105211-A1 | INHIBITORS OF HEDGEHOG PATHWAY | EXELIXIS, INC. (US) | 2009-04-23 | — | — | US | disclosed |
| WO-2008112913-A1 | INHIBITORS OF THE HEDGEHOG PATHWAY | EXELIXIS, INC. (US) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008112913-A1 | INHIBITORS OF THE HEDGEHOG PATHWAY | EXELIXIS, INC. (US) | 2008-09-18 | — | — | WO | disclosed |
| US-20050070459-A1 | treating Type I diabetes, septic shock, multiple sclerosis, inflammatory bowel disease (IBD) and Crohn's disease with BoroProline-Pinacol or other proline derivatives; dipeptidylpeptidase inhibitor | BRIGHAM AND WOMEN"S HOSPITAL (US) | 2005-03-31 | — | — | US | disclosed |
| EP-1487471-A2 | METHODS FOR TREATING AUTOIMMUNE DISORDERS AND REAGENTS RELATED THERETO | Trustees of Tufts College (US) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003045228-A9 | METHODS FOR TREATING AUTOIMMUNE DISORDERS, AND REAGENTS RELATED THERETO | TUFTS COLLEGE (US) | 2004-09-16 | — | — | WO | disclosed |
| WO-2003045228-A2 | METHODS FOR TREATING AUTOIMMUNE DISORDERS, AND REAGENTS RELATED THERETO | TRUSTEES OF TUFTS COLLEGE (US) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105211-A1 | INHIBITORS OF HEDGEHOG PATHWAY | SHH, GLI1, SMO | ANPEP 4223/4885DPP4 2994/4885ALDH1A1 1523/4885 |
| US-20050070459-A1 | treating Type I diabetes, septic shock, multiple sclerosis, inflammatory bowel disease (IBD) and Crohn's disease with BoroProline-Pinacol or other proline derivatives; dipeptidylpeptidase inhibitor | DNPEP, PREP, VIP | ANPEP 21/4885DPP4 11/4885ALDH1A1 3157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.